PROGRAMME AND PRICES 2026

You can download the programme and prices here as a pdf “ECAT Programme and prices 2026“
#    Prices are excluding VAT and including shipping costs by regular service.

Details MG1

Set A:   
– FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025)
– FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963)
– Methylenetetrahydrofolate reductase (MTHFR)
– MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133)
– MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131)
– PAI-I 4G5G (SERPINE1, NM_000602.5:c.-820G[(4_5)], rs1799762)

Set B:   
– FXIII V34L (F13A1, NM_000129.4:c.103G>T, rs5985)
– GPIIIa (ITGB3, NM_000212.3:c.176T>C, rs5918)
– beta-Fibrinogen g-455a (FGB, NM_005141.4:c.-463G>A, rs1800790)
– Vitamin K epoxide reductase complex subunit 1 (VKORC1)
– VKORC1 G-1639 (VKORC1, NM_024006.6:c.-1639G>A, rs9923231)
– VKORC1 C1173T (VKORC1, NM_024006.6:c.174-136C>T, rs9934438)
– FXII c46t (F12, NM_000505.4:c.-4T>C rs1801020)
– FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595)

Set C:     
– Alpha-1-Antitrypsin, (serpin family A member1)
– AAT-PI*S (SERPINA1, NM_000295.5:c.863A>T, rs17580)
– AAT-PI*Z (SERPINA1, NM_000295.5:c.1096G>A, rs28929474)
– AAT – Genotyping
– AAT- (Alpha-1-Antitrypsin-Genotyping)
– Apolipoprotein E (APOE)
– ApoE2 (APOE, NM_000041.4:c.526C>T, rs7412)
– ApoE4 (APOE, NM_000041.4:c.388T>C, rs429358)
– ApoE – Genotyping
– ApoB100 (APOB, NM_000384.3:c.10580G>A, rs5742904)
– ACE I/D (ACE, NM_000789.3:c.2306-117_2306-116insAF118569.1:g.14094_14382, rs1799752)
– CETP B1/B2 (CETP, NM_000078.3:c.118+279G>A, rs708272)

 Set D:     
–Aldolase, fructose-bisphosphate B (ALDOB )
– AldoB 149 (ALDOB, NM_000035.4:c.448G>C, rs1800546)
– AldoB 174 (ALDOB, NM_000035.4:c.524C>A, rs76917243)
– AldoB 334 (ALDOB, NM_000035.4:c.1005C>G, rs78340951)
 Hereditary Hemochromatosis (HFE)
– HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945)
– HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562)
– LCT c-13910t (LCT, NM_005915.6:c.1917+326C>T, rs4988235)
 Nucleotide binding oligomerization domain containing 2 (NOD2)
– NOD R702W (NOD2, NM_001370466.1:c.2023C>T, rs2066844)
– NOD G908R (NOD2, NM_001370466.1:c.2641G>C, rs2066845)
– NOD L1007finsC (NOD2, NM_001370466.1:c.2938dup, rs2066847)

Set E:   
– ATP7B-C3207A (ATP7B, NM_000053.4:c.3207C>A, rs76151636)
– FSAP Marburg-I (HABP2, NM_004132.5:c.1601G>A, rs7080536)
– ITGA2 GpIaIIa C807T (ITGA2, NM_002203.4:c.759C>T, rs1126643)
– Col1A1 SP1 (Col1A1, NM_000088.4:c.104-441G>T, rs1800012)
  Vitamin D receptor (VDR)
– VDR BsmI (VDR, NM_000376.3:c.1024+283G>A, rs1544410)
– VDR ApaI (VDR, NM_000376.3:c.1025-49G>T, rs7975232)
– VDR TaqI (VDR, NM_000376.3:c.1056T>C, rs731236)

Set F:    
– Faktor VII (R353Q) (F7, NM_019616.4:c.1172G>A, rs6046)
– AT3 Cambridge Typ I/II (SERPINC1, NM_000488.4:c.1246G>C>T, rs121909548)
– CYP3A5*3 (CYP3A5, NM_000777.5:c.219-237A>G, rs776746

Details MG2

Set A:     
Thiopurine S-methyltransferase (TPMT)
– TPMT*2 (TPMT, NM_000367.5:c.238G>C, rs1800462)
– TPMT*3B (TPMT, NM_000367.5:c.4G>A, rs1800460)
– TPMT*3C (TPMT, NM_000367.5:c.719A>G, rs1142345)
– TPMT – Genotyping
– CYP2C8*3 (CYP2C8, NM_000770.3:c.1196A>G, rs10509681)
  Cytochrom P450 2C9 (CYP2C9)
– CYP2C9*2 (CYP2C9, NM_000771.4:c.430C>T, rs1799853)
– CYP2C9*3 (CYP2C9, NM_000771.4:c.1075A>C, rs1057910)
– CYP2C9 – Genotyping
– UGT1A1*28 (UGT1A1, NM_000463.3:c.-41_-40dupTA, rs3064744)
  Dihydropyrimidine dehydrogenase (DPYD)
– DPYD*2A (DPYD, NM_000110.4:c.1905+1G>A, rs3918290)
– DPYD*13 (DPYD, NM_000110.4:c.1679T>G, rs55886062)
– DPYD p.D949V (DPYD, NM_000110.4:c.2846A>T, rs67376798)
– DPYD c.1129-5923C>G (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182)
– DPYD c.1236G>A (DPYD, NM_000110.4:c.1236G>A, rs56038477)
– DPYD HapB3 (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182,
  NM_000110.4:c.1236G>A, rs56038477)
– DPD activity score acc. to CPIC
– DPD activity score acc. to DGHO
– BCHE A (D70G) (BCHE, NM_000055.4:c.293A>G, rs1799807)
– BCHE K (A567T) (BCHE, NM_000055.4:c.1699G>A, rs1803274)

Set B:     
– KRAS proto-oncogene, GTPase (KRAS)
– KRAS p.G12/p.G13 (KRAS, NP_004976.2:p.G12/G13)
– KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530)
– KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529)
– KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535)
– KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441)
– KRAS p.G12 (KRAS, NP_004976.2:p.G12)
– KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530)
– KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529)
– KRAS p.G13 (KRAS, NP_004976.2:p.G13)
– KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535)
– KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441)
– KRAS p.Q61 (KRAS, NP_004976.2:p.Q61)
– KRAS p.Q61 (KRAS, NM_004985.5:c.181C>G>A, rs121913238)
– KRAS p.Q61 (KRAS, NM_004985.5:c.182A>T>G>C, rs121913240)
– KRAS p.Q61 (KRAS, NM_004985.5:c.183A>T>C, rs17851045)
  BRAF p.V600 (BRAF, NP_004324.2:p.V600E/K)
– BRAF V600E (BRAF, NM_004333.6:c.1799T>A, rs113488022)
– BRAF V600K (BRAF, NM_004333.6:c.1798_1799delinsAA, rs121913227)
– c-KIT p.D816V (KIT, NM_000222.3:c.2447A>T, rs121913507)
– NRAS (NRAS, NP_002515.1:p.Q61)
– NRAS (NRAS, NM_002524.5:c.181C>T>G>A, rs121913254)
– NRAS (NRAS, NM_002524.5:c.182A>T>G>C, rs11554290)
– NRAS (NRAS, NM_002524.5:c.183A>T>C, rs121913255)

Set C: 
– HLA-B*27:01 (HLA-B, NM_005514.8)
– TNF alpha 238 (TNF, NM_000594.3:c.-418G>A, rs361526)
– TNF alpha 308 (TNF, NM_000594.3:c.-488G>A, rs1800629)

Set D:     
–Cytochrome P450 2D6 (CYP2D6)
– CYP2D6*2-296 (CYP2D6*2, NM_000106.6:c.886C>T, rs16947)
– CYP2D6*2-486 (CYP2D6*2, NM_000106.6:c.1457G>C, rs1135840)
– CYP2D6*3 (CYP2D6*3, NM_000106.6:c.775del, rs35742686)
– CYP2D6*4 (CYP2D6*4, NM_000106.6:c.506-1G>A, rs3892097)
– CYP2D6*6 (CYP2D6*6, NM_000106.6:c.454del, rs5030655)
– CYP2D6*7 (CYP2D6*7, NM_000106.6:c.971A>C, rs5030867)
– CYP2D6*8 (CYP2D6*8, NM_000106.6:c.505G>T, rs5030865)
– CYP2D6*9 (CYP2D6*9, NM_000106.6:c.841_843del, rs5030656)
– CYP2D6*10 (CYP2D6*10, NM_000106.6:c.100C>T, rs1065852)
– CYP2D6*17 (CYP2D6*17, NM_000106.6:c.320C>T, rs28371706)
– CYP2D6*35 (CYP2D6*35, NM_000106.6:c.31G>A, rs769258)
– CYP2D6*41 (CYP2D6*41, NM_000106.6:c.985+39G>A, rs28371725)
– CYP2D6*5 (CYP2D6, Deletion)
– CYP2D6*xN (CYP2D6, Duplication/Amplification)
  Cytochrome P450 2C19 (CYP2C19)
– CYP2C19*2 (CYP2C19, NM_000769.4:c.681G>A, rs4244285)
– CYP2C19*3 (CYP2C19, NM_000769.4:c.636G>A, rs4986893)
– CYP2C19*17 (CYP2C19, NM_000769.4:c.-806C>T, rs12248560)
– CYP2C19 – Genotyping

Set E:   
– HLA-B*57:01 (HLA-B, NM_005514.8)
  Cytochrome P450 2B6 (CYP2B6)
– CYP2B6*4 (CYP2B6, NM_000767.5:c.785A>G, rs2279343)
– CYP2B6*9 (CYP2B6, NM_000767.5:c.516G>T, rs3745274)
– CYP2B6*6 (CYP2B6, NM_000767.5:c.785A>G, rs2279343 + NM_000767.5:c.516G>T, rs3745274)
– ABCB1 c.3435T>C (ABCB1, NM_001348946.2:c.3435T>C, rs1045642)
– CCR5-del32bp (CCR5, NM_001394783.1:c.554_585del, rs333)

Set F:    

– IL28B (C/T Polymorphism) (IFNL4, NM_001276254.2:c.151-152G>A, rs12979860)
– IL6 G(-174)C (IL6, NM_000600.4:c.-237C>G, rs1800795)
– CYP3A4*22 (CYP3A4, NM_017460.6:c.522-191C>T, rs35599367)

Details DNA Isolation and genotyping
– FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025)
– FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595)
– FV-Cambridge (F5, NM_000130.5:c.1001G>C, rs118203906)
– FV-Hong-Kong (F5, NM_000130.5:c.1000A>G, rs118203905)
– FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963)
– Methylenetetrahydrofolate reductase (MTHFR
– MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133)
– MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131)
  Hereditary Hemochromatosis (HFE)
– HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945)
– HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562)